A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

B. J. Eigl, S. North, E. Winquist, D. Finch, L. Wood, S. S. Sridhar, J. Powers, J. Good, M. Sharma, J. A. Squire, J. Bazov, T. Jamaspishvili, M. E. Cox, P. A. Bradbury, E. A. Eisenhauer, K. N. Chi